How Bioxodes is positioning BIOX-101 for accelerated approval in intracerebral hemorrhage
Can BIOX-101 become the first disease-modifying therapy for intracerebral hemorrhage? Explore Bioxodes’ accelerated approval strategy.
Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
Bioxodes advances BIOX-101 into pivotal trials for intracerebral hemorrhage. Find out how this strategy could reshape stroke treatment pathways.
Revalesio’s RNS60 program signals renewed momentum in adjunctive stroke therapeutics
Revalesio presents new RNS60 stroke data showing reduced brain tissue loss and shorter hospital stays. Discover what this could mean for stroke drug development.